

## ON THE STRUCTURE OF THE STABLE COMPLEX BETWEEN PLASMIN AND $\alpha_2$ -ANTIPLASMIN

Torbjörn NILSSON and Björn WIMAN\*

*Department of Clinical Chemistry, Umeå University Hospital, S-901 85 Umeå, Sweden*

Received 13 April 1982

### 1. Introduction

Many of the protease inhibitors in plasma form extremely stable complexes with proteolytic enzymes, which cannot be dissociated by strong denaturing agents [1–4]. Many of these complexes are, however, dissociated by nucleophilic agents; a covalent bond may be involved in their stabilization [1,2]. This has also been suggested for inhibitors such as soybean trypsin inhibitor and aprotinin in their complexes with proteases [5,6]. The reaction between plasmin and  $\alpha_2$ -antiplasmin was investigated by a number of kinetic [7–9] and structural studies [10]. The kinetic data have revealed a two-step reaction: (i) a very fast reversible second-order reaction; followed by (ii) a slower irreversible transition [7–9]. The structural data have indicated that the reactive site in  $\alpha_2$ -antiplasmin constitutes a specific leucyl-methionyl residue in the carboxy-terminal portion of the molecule [10].  $\alpha_2$ -Antiplasmin and its interactions are reviewed in [11]. This study was done to investigate whether the reactive site in  $\alpha_2$ -antiplasmin is cleaved as a result of complex formation with plasmin. Part of this work has been presented in [12].

### 2. Materials and methods

#### 2.1. Plasminogen

Glu-plasminogen was purified by affinity chromatography on lysine-Sepharose [13] followed by DEAE-Sephadex A-50 chromatography [14]. It was characterized by SDS-polyacrylamide gel electrophoresis and  $\text{NH}_2$ -terminal amino acid determination.

#### 2.2. $\alpha_2$ -Antiplasmin

$\alpha_2$ -Antiplasmin was purified by affinity chromatography on LBS I-Sepharose followed by gel-filtration on Ultrogel AcA 44, as in [11,15]. LBS I is a fragment from plasminogen constituting the 3  $\text{NH}_2$ -terminal triple-loop structures obtained after digestion with elastase [16]. The material was characterized by SDS-polyacrylamide gel electrophoresis and  $\text{NH}_2$ -terminal amino acid analysis and found to fulfill the specifications in [15].

#### 2.3. Complexes between Glu-plasmin and protease inhibitors

To obtain Glu-plasmin complexes with  $\alpha_2$ -antiplasmin or soybean trypsin inhibitor, a mixture of Glu-plasminogen (final conc.  $\sim 10$  mg/ml) and the inhibitor in  $\sim 50\%$  molar excess were dissolved in 0.1 M sodium phosphate buffer (pH 7.3). Activation was performed by the addition of urokinase (final conc. 2500 IU/ml) and incubation at room temperature for 2 h. The material was subsequently dialyzed extensively against distilled water at  $+5^\circ\text{C}$  and lyophilized.

#### 2.4. Reagents

Soybean trypsin inhibitor was purchased from Sigma (St Louis MO). Urokinase was a gift from Choay (Paris, courtesy of Dr F. Toulemonde).  $\text{Na}^{125}\text{I}$  was from Kebo AB (Stockholm) and  $^3\text{H}$ -labelled phenylisothiocyanate from The Radiochemical Centre (Amersham). All other reagents were of analytical grade.

#### 2.5. SDS-polyacrylamide gel electrophoresis

This was performed essentially as in [17] using 7% polyacrylamide gels on reduced as well as non-reduced samples. After staining, the gels containing  $^{125}\text{I}$ -labelled

\* To whom correspondence should be addressed

material were cut into slices representing the different interesting protein bands and the radioactivity was counted in a Multigamma counter (LKB, Stockholm).

### 2.6. *NH<sub>2</sub>-terminal amino acid analysis*

*NH<sub>2</sub>*-Terminal amino acids were determined by manual Edman degradation essentially as in [18]. The phenylthiohydantoin amino acid derivatives were identified by thin-layer chromatography on silica gel plates, as in [19]. Radioactive derivatives were quantitated by scraping off the silica containing the different spots, adding 5 ml scintillation liquid (Instagel, Packard Instruments) and counting in a liquid counter (Intertechnique, SL4000). Quantitation of amino acid phenylthiohydantoin derivatives were performed by amino acid analysis (LKB, Biochrom 4400) after hydrolysis for 4 h at 150°C in 6 M HCl containing 0.1% stannous chloride [20].

## 3. Results

### 3.1. *NH<sub>2</sub>-terminal amino acids in soybean trypsin inhibitor or $\alpha_2$ -antiplasmin in complex with plasmin*

As a first step to find out the nature of the stabilizing bond in different plasmin-inhibitor complexes, these were subjected to *NH<sub>2</sub>*-terminal amino acid determination. About equal amounts of glutamic acid, valine and aspartic acid in ~1 mol/mol soybean trypsin inhibitor-plasmin complex were found (table 1). This represents the *NH<sub>2</sub>*-terminal amino acid in the parent molecules. However, in the plasmin- $\alpha_2$ -anti-

plasmin complex, besides the expected *NH<sub>2</sub>*-terminal amino acids (glutamic acid, valine and asparagine) methionine was also found at ~1 mol/mol complex.

### 3.2. *Dissociation of soybean trypsin inhibitor-plasmin complex in the presence of $\alpha_2$ -antiplasmin*

If soybean trypsin inhibitor-plasmin complex is mixed with  $\alpha_2$ -antiplasmin in molar excess the plasmin is completely transferred into a complex with  $\alpha_2$ -antiplasmin. The *NH<sub>2</sub>*-terminal amino acids in such a complex are demonstrated in table 1. By gel-filtration on Ultrogel AcA 44 in 0.1 M  $\text{NH}_4\text{HCO}_3$  the plasmin- $\alpha_2$ -antiplasmin complex can be separated from the released soybean trypsin inhibitor. Only *NH<sub>2</sub>*-terminal aspartic acid is found in the latter inhibitor-moiety, which is identical to the native soybean trypsin inhibitor preparation. Furthermore, analysis of the released soybean trypsin inhibitor by SDS-polyacrylamide gel electrophoresis (reduced and non-reduced samples) demonstrated a single chain molecule with a mobility identical to that of the native molecule. Analysis of its inhibitory activity against plasmin revealed that ~90% activity was retained.

To exclude the possibility of secondary proteolytic cleavage by plasmin as a cause of peptide bond cleavage in  $\alpha_2$ -antiplasmin during its reaction with plasmin, the following experiments were undertaken. <sup>125</sup>I-Labelled Glu-plasmin in complex with soybean trypsin inhibitor was dissolved in 4.5% (v/v) dimethylallylamine buffer (adjusted with trifluoroacetic acid to pH 8.0) to 10 mg/ml final conc. and mixed with an equal volume of  $\alpha_2$ -antiplasmin solution (9 mg/ml in the same buffer). At different times, over 0-4 h, samples were taken for SDS-polyacrylamide gel electrophoresis and for *NH<sub>2</sub>*-terminal amino acid determination. After staining the gels, the bands comprising plasmin and plasmin- $\alpha_2$ -antiplasmin complex were cut out and counted for radioactivity. From the results, shown in fig.1, the dissociation of the soybean trypsin inhibitor-plasmin complex was found to obey first-order kinetics with a half-life of ~60 min, which equals a rate constant of  $2 \times 10^{-4} \text{ s}^{-1}$ . Within experimental error, the appearance of methionine as new *NH<sub>2</sub>*-terminal amino acid is concomitant with the formation of the plasmin- $\alpha_2$ -antiplasmin complex (fig.1).

### 3.3. *Pulse labelling of plasmin- $\alpha_2$ -antiplasmin with [<sup>3</sup>H]phenylisothiocyanate*

In an attempt to show that *NH<sub>2</sub>*-terminal methionine is not produced during the coupling step of the

Table 1

Amino acid	a	b	c	d
Aspartic acid	—	1.5	2.2	1.0
Glutamic acid	0.9	0.7	0.7	—
Valine	—	1.0	1.0	—
Methionine	0.1	0.1	1.0	—
Isoleucine	—	0.1	0.1	—

*NH<sub>2</sub>*-terminal amino acids in: plasminogen (a); the complex between plasmin and soybean trypsin inhibitor, obtained by activation of plasminogen in ~50% molar excess of the inhibitor (b); plasmin- $\alpha_2$ -antiplasmin complex obtained by incubation (16 h) of the plasmin-soybean trypsin inhibitor complex (50% excess inhibitor) with an equimolar amount of  $\alpha_2$ -antiplasmin (c); soybean trypsin inhibitor obtained after dissociation of the soybean trypsin inhibitor-plasmin complex by  $\alpha_2$ -antiplasmin (d). Figures are expressed in mol/mol protein (a,d) or mol/mol complex (b,c)




Fig.1. Dissociation of the plasmin-soybean trypsin inhibitor complex in the presence of  $\alpha_2$ -antiplasmin as demonstrated by the formation of plasmin- $\alpha_2$ -antiplasmin complex (o—o) and the appearance of new  $\text{NH}_2$ -terminal methionine (●—●). For details of the experiments see text. The figures are given as ratios between the plasmin- $\alpha_2$ -antiplasmin complex/the initial plasmin-soybean trypsin inhibitor complex and methionine/valine, respectively.

$\text{NH}_2$ -terminal amino acid analysis, but exists in the native complex, a pulse-labelling experiment with [ $^3\text{H}$ ]phenylisothiocyanate was done. For this purpose plasmin- $\alpha_2$ -antiplasmin complex was dissolved in 0.01 M sodium phosphate buffer (pH 7.8) to 20 mg/ml final conc. and divided into 250  $\mu\text{l}$  aliquots. A solution (0.5 ml) of pyridine and dimethylallylamine (15/1, v/v) adjusted with trifluoroacetic acid to pH 9.2, containing 0.1  $\mu\text{l}$  [ $^3\text{H}$ ]phenylisothiocyanate/ml was added at 45°C. After a certain reaction time, from 0.5–5 min, 100  $\mu\text{l}$  non-labelled phenylisothiocyanate was added and incubation was carried out for another 60 min at 45°C in a nitrogen atmosphere. Subsequently, a normal  $\text{NH}_2$ -terminal amino acid analysis was performed. The specific radioactivity of the different  $\text{NH}_2$ -terminal amino acids derivatives were plotted against the reaction time (fig.2). The rate of the labelling of  $\text{NH}_2$ -terminal methionine, within experimental errors, equals that of the other  $\text{NH}_2$ -terminal amino acids (Asn, Asp, Glu, Val) in the complex, indicating its existence already in the native complex. For simplicity only the results with methionine and valine are demonstrated in fig.2.




Fig.2. Rate of [ $^3\text{H}$ ]phenylisothiocyanate labelling of methionine (■—■) as compared to valine (○—○) in the plasmin- $\alpha_2$ -antiplasmin complex. For details of the experiment see text.

#### 4. Discussion

Structural studies on the plasmin- $\alpha_2$ -antiplasmin complex have indicated that the reactive site in  $\alpha_2$ -antiplasmin constitutes a specific peptide bond in the carboxy-terminal portion of the molecule [10–12]. A peptide of  $\sim 8000 M_r$  and  $\text{NH}_2$ -terminal methionine, originating from the carboxy-terminal end of  $\alpha_2$ -antiplasmin could be isolated by gel-filtration of the complex in the presence of SDS or after treatment with diluted  $\text{NH}_4\text{OH}$  [10]. The peptide could, however, not be isolated by gel-filtration in 10% acetic acid or in buffers containing urea or guanidinium-HCl. Therefore, we undertook this work to investigate whether the reactive-site peptide bond in  $\alpha_2$ -antiplasmin becomes cleaved as a result of complex formation with plasmin. From indirect evidence it had been suggested that an ester-bond may be of importance in the stabilization of many protease-inhibitor complexes, since they are cleaved by agents such as hydroxylamine, benzamidine, weak alkali or methoxyamine [1,2,10,21]. Of course, a tetrahedral intermediate could not be excluded from these results.

This study demonstrates a difference in the binding of plasmin to  $\alpha_2$ -antiplasmin as compared to soybean trypsin inhibitor, the former being much more stable. Dissociation of the plasmin-soybean trypsin inhibitor complex by  $\alpha_2$ -antiplasmin releases an intact form of soybean trypsin inhibitor. Furthermore, our data show that formation of the stable complex between

plasmin and  $\alpha_2$ -antiplasmin is accompanied by cleavage of the reactive-site peptide bond, since the appearance of  $\text{NH}_2$ -terminal methionine parallels the complex formation (fig.1).

Crystallographic data have suggested that complexes between trypsin and inhibitors such as soybean trypsin inhibitor or aprotinin are stabilized by the formation of a tetrahedral intermediate [5,6]. These data were, however, not supported by  $^{13}\text{C}$  NMR studies [22], which rather indicated that non-covalent bonds stabilize these inhibitor-protease complexes. Our data exclude a tetrahedral intermediate as being important in the plasmin- $\alpha_2$ -antiplasmin interaction. An ester-bond between the hydroxyl-group in the active site of plasmin and the carboxyl-group of the peptide bond in the reactive site is much more plausible, in agreement with earlier speculations [1,2]. However, the explanation for the stability of this ester-bonded intermediate is not known, but several mechanisms are possible. One explanation may be that a very tight complex is formed which does not leave any space for the water molecule necessary to hydrolyze the ester-bond. However, it has been reported that the complex between, e.g., thrombin and antithrombin III can be dissociated by benzamidine or hydroxylamine [1,2] for example. These substances do not interfere with the plasmin- $\alpha_2$ -antiplasmin complex at physiological pH under non-denaturing condition. Nevertheless, in the presence of SDS, hydroxylamine seems to cleave the plasmin- $\alpha_2$ -antiplasmin complex (Wiman and Collen, unpublished). Another possible explanation of the stability of the ester-bond is that cleavage of the reactive site peptide bond results in conformational changes, thus interfering with the electron-relay system within the catalytic center of the enzyme. We have shown that conformational changes are likely to occur as a result of complex formation between and  $\alpha_2$ -antiplasmin as studied by immunochemical [23,24] or spectropolarimetric investigations [25]. Work to isolate a fragment from the complex containing the bond between plasmin and  $\alpha_2$ -antiplasmin is in progress.

#### Acknowledgements

Financial support has been obtained by the Swedish Medical Research Council (project 05193), The Medical Faculty, University of Umeå and The Lions Research Foundation, Department of Oncology, University of Umeå (projects 179/80 and 206/81).

Expert technical assistance by Ms Åsa Almqvist is gratefully acknowledged.

#### References

- [1] Moroi, M. and Yamasaki, M. (1974) *Biochim. Biophys. Acta* 359, 130–146.
- [2] Owen, W. G. (1975) *Biochim. Biophys. Acta* 405, 380–387.
- [3] Morio, M. and Aoki, N. (1976) *J. Biol. Chem.* 152, 5956–5965.
- [4] Wiman, B. and Collen, D. (1977) *Eur. J. Biochem.* 78, 19–26.
- [5] Huber, R., Kukla, D., Steigemann, W., Deisenhofer, J. and Jones, A. (1974) in: *Proteinase Inhibitors* (Fritz, H. et al. eds) pp. 497–512, Springer-Verlag, Berlin, New York.
- [6] Janin, J., Sweet, R. M. and Blow, D. M. (1974) in: *Proteinase Inhibitors* (Fritz, H. et al. eds) pp. 513–520, Springer-Verlag, Berlin, New York.
- [7] Wiman, B. and Collen, D. (1978) *Eur. J. Biochem.* 84, 573–578.
- [8] Wiman, B., Boman, L. and Collen, D. (1978) *Eur. J. Biochem.* 87, 143–146.
- [9] Christensen, U. and Clemmensen, I. (1978) *Biochem. J.* 175, 635–641.
- [10] Wiman, B. and Collen, D. (1979) *J. Biol. Chem.* 254, 9291–9297.
- [11] Wiman, B. (1981) *Methods Enzymol.* 80, 395–408.
- [12] Wiman, B., Nilsson, T. and Collen, D. (1980) *Protides Biol. Fluids* 28, 379–382.
- [13] Deutsch, D. G. and Mertz, E. T. (1970) *Science* 170, 1095–1096.
- [14] Wallén, P. and Wiman, B. (1972) *Biochim. Biophys. Acta* 257, 122–134.
- [15] Wiman, B. (1980) *Biochem. J.* 191, 229–232.
- [16] Sottrup-Jensen, L., Claeys, H., Zajdel, M., Petersen, T. E. and Magnusson, S. (1978) in: *Progress in Chemical Fibrinolysis and Thrombolysis* (Davidson, J. F. et al. eds) vol. 3, pp. 191–209, Raven, New York.
- [17] Weber, K. and Osborn, M. (1969) *J. Biol. Chem.* 244, 4406–4412.
- [18] Edman, P. and Henschen, A. (1975) in: *Protein Sequence Determination* (Needleman, S. B. ed) pp. 232–279, Springer-Verlag, Berlin, New York.
- [19] Wiman, B. (1977) *Eur. J. Biochem.* 76, 129–137.
- [20] Lai, C. Y. (1977) *Methods Enzymol.* 48, 369–373.
- [21] Longas, M. O. and Finlay, T. H. (1980) *Biochem. J.* 189, 481–489.
- [22] Hunkapiller, M. W., Forgacs, M. D., Ho Yu, E. and Richards, J. H. (1979) *Biochem. Biophys. Res. Commun.* 87, 25–31.
- [23] Plow, E., Wiman, B. and Collen, D. (1980) *J. Biol. Chem.* 255, 2902–2906.
- [24] Wiman, B. and Jacobsson, L. (1981) in: *Progress in Chemical Fibrinolysis and Thrombolysis* (Davidson, J. F. et al. eds) vol. 5, pp. 164–168, Churchill-Livingstone, Edinburgh.
- [25] Nilsson, T., Sjöholm, I. and Wiman, B. (1982) submitted.